[HTML][HTML] L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature

…, P Gaulard, B Marin, N Gachard, D Bordessoule… - Annals of oncology, 2009 - Elsevier
Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-
cell leukemia are highly aggressive diseases with a poor outcome. Patients and methods …

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a …

…, C Sebban, K Belhadj, D Bordessoule… - Blood, The Journal …, 2010 - ashpublications.org
We report the outcome of patients included in the LNH-98.5 study, which compared
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus …

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

…, DB Yehuda, F Benedetti, P Borchman, D Bordessoule… - The Lancet, 2019 - thelancet.com
Background Based on the encouraging activity and manageable safety profile observed in a
phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …

Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpura

…, GA Millot, C Daubin, D Bordessoule… - British journal of …, 2006 - Wiley Online Library
In order to assess the prognostic value of inhibitory anti‐ADAMTS13 antibodies in
thrombotic thrombocytopenic purpura (TTP), we performed a multicentre prospective study …

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

…, C Pautas, C Terré, E Raffoux, D Bordessoule… - The Lancet, 2012 - thelancet.com
Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody
conjugate, to the standard treatment for patients with acute myeloid leukaemia in phase 3 …

[HTML][HTML] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

…, J Tanzer, M Navarro, D Bordessoule… - … England Journal of …, 1997 - Mass Medical Soc
Background Treatment with interferon prolongs survival in chronic myelogenous leukemia.
We conducted a clinical trial to assess the efficacy of treatment with a combination of …

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly …

…, E Solary, N Fegueux, D Bordessoule… - Blood, The Journal …, 1999 - ashpublications.org
All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 …

…, G Lepeu, C Fruchart, D Bordessoule… - The Lancet …, 2011 - thelancet.com
Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although
treatment has been standardised in younger patients, no prospective study has been done …

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion

…, MT Caulier, E Wattel, D Bordessoule… - Blood, The Journal …, 1998 - ashpublications.org
Abstract Treatment with alkylating agents or radiophosphorous (32P) has been shown to
carry a certain leukemogenic risk in myeloproliferative disorders (MPDs), including essential …

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a …

…, P Gaulard, J Feuillard, D Bordessoule… - Blood, The Journal …, 2011 - ashpublications.org
Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a
grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report …